• TheraVida has developed a proprietary and patent-protected product, where a positive-acting agent (“agonist”) with a delayed-onset, immediate-release profile is added to an inhibiting agent (“antagonist”) to create a combination therapeutic with a goal of reducing or eliminating problematic side effects for patients.


  • THVD-102 is our lead candidate for the treatment of primary focal hyperhidrosis and has completed a Phase 2 trial. It has the potential to address patients suffering from both primary and secondary hyperhidrosis. It is the only oral, systemically acting drug for primary focal hyperhidrosis in development. Botox®, the only marketed prescription product for hyperhidrosis is locally injected and only approved for the axillary form. Other development stage products are for topical administration and also target axillary hyperhidrosis.